- Home
- GNTA vs NOTV Comparison
GNTA vs NOTV Comparison
Compare GNTA & NOTV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- GNTA
- NOTV
- Stock Information
- Founded
- GNTA 2014
- NOTV 1974
- Country
- GNTA Italy
- NOTV United States
- Employees
- GNTA N/A
- NOTV N/A
- Industry
- GNTA Biotechnology: Biological Products (No Diagnostic Substances)
- NOTV Biotechnology: Pharmaceutical Preparations
- Sector
- GNTA Health Care
- NOTV Health Care
- Exchange
- GNTA Nasdaq
- NOTV Nasdaq
- Market Cap
- GNTA 81.2M
- NOTV 69.4M
- IPO Year
- GNTA 2021
- NOTV 1997
- Fundamental
- Price
- GNTA $3.87
- NOTV $2.03
- Analyst Decision
- GNTA Strong Buy
- NOTV Strong Buy
- Analyst Count
- GNTA 1
- NOTV 1
- Target Price
- GNTA $25.00
- NOTV $5.00
- AVG Volume (30 Days)
- GNTA 28.5K
- NOTV 770.3K
- Earning Date
- GNTA 01-01-0001
- NOTV 08-07-2025
- Dividend Yield
- GNTA N/A
- NOTV N/A
- EPS Growth
- GNTA N/A
- NOTV N/A
- EPS
- GNTA N/A
- NOTV N/A
- Revenue
- GNTA N/A
- NOTV $480,402,000.00
- Revenue This Year
- GNTA N/A
- NOTV $4.99
- Revenue Next Year
- GNTA N/A
- NOTV $5.39
- P/E Ratio
- GNTA N/A
- NOTV N/A
- Revenue Growth
- GNTA N/A
- NOTV N/A
- 52 Week Low
- GNTA $2.74
- NOTV $1.15
- 52 Week High
- GNTA $7.28
- NOTV $6.48
- Technical
- Relative Strength Index (RSI)
- GNTA 56.78
- NOTV 46.28
- Support Level
- GNTA $2.74
- NOTV $1.66
- Resistance Level
- GNTA $3.39
- NOTV $3.19
- Average True Range (ATR)
- GNTA 0.28
- NOTV 0.20
- MACD
- GNTA 0.05
- NOTV -0.04
- Stochastic Oscillator
- GNTA 94.17
- NOTV 40.11
About GNTA Genenta Science S.p.A.
Genenta Science SPA is a clinical-stage biotechnology company engaged in the development of hematopoietic stem cell gene therapies for the treatment of solid tumors and cancer. The company's products include Temferon - a product to treat glioblastoma multiforme, a solid tumor affecting the brain.
About NOTV Inotiv Inc.
Inotiv Inc is a pharmaceutical development company specializing in nonclinical and analytical drug discovery, development services to the pharmaceutical, chemical, and medical device industries. It operates in two segments; Discovery and Safety Assessment (DSA) and Research Models and Services (RMS). Through the DSA segment, the company supports the discovery, nonclinical development, and clinical development needs of researchers and clinicians for small molecule drug candidates, biotherapeutics, and biomedical devices. Through the RMS segment, the company offers access to a wide range of small and large research models for basic research, drug discovery, development, and specialized models for specific diseases and therapeutic areas. The company earns maximum revenue from RMS Segment.